The management of diabetes has evolved significantly over the years, with new medications continually being developed to enhance treatment efficacy and improve patient outcomes. Among these advancements, SGLT2 inhibitors have emerged as a pivotal class of medications for managing Type 2 diabetes. These drugs work by promoting the excretion of glucose through urine, thereby lowering blood sugar levels. Canagliflozin and Dapagliflozin are two prominent medications within this class, each with distinct profiles and benefits. Both of these medications have garnered attention for their ability not only to control blood sugar but also to provide additional cardiovascular and renal benefits. As the prevalence of diabetes continues to rise globally, understanding the…